Addex Therapeutics (ADXN) Depreciation & Amortization (CF) (2019 - 2026)

Addex Therapeutics has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $12.5 billion in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 432.32% year-over-year to $12.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 billion (up 113.78% YoY) and the FY2025 annual result came in at $10218.3, down 96.54% from the prior year.
• Depreciation & Amortization (CF) advanced to $12.5 billion in Q1 2026 per ADXN's latest filing, from -$2.6 billion in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $272.8 billion in Q3 2024 and troughed at -$269.8 billion in Q4 2024.
• A 5-year average of $1.1 billion and a median of $86537.6 in 2022 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 194303126.57% in 2023, down 325276525.18% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $78524.3 in 2022, then sank by 325276525.18% to -$255.4 billion in 2023, then retreated by 5.61% to -$269.8 billion in 2024, then soared by 99.05% to -$2.6 billion in 2025, then jumped by 590.18% to $12.5 billion in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $12.5 billion, -$2.6 billion, and $2.4 billion for Q1 2026, Q2 2025, and Q1 2025 respectively.